Mifepristone丨CAS 84371-65-3

1. Medical Termination of Pregnancy
● Primary clinical use: Mifepristone丨CAS 84371-65-3 is FDA-approved for medical abortion during the first trimester (up to 10 weeks gestation), in combination with misoprostol.
● Mechanism: Blocks progesterone receptors, preventing the hormone from maintaining the uterine lining, leading to detachment of the embryo.
● When followed by misoprostol (a prostaglandin analogue), it induces uterine contractions and expulsion of pregnancy tissue.
2. Cushing's Syndrome (Hyperglycemia Management)
● Mifepristone is approved under the trade name Korlym for managing hyperglycemia secondary to Cushing's syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery.
● Mechanism: Acts as a glucocorticoid receptor antagonist, helping mitigate the effects of excessive cortisol.
3. Research in Endocrinology and Oncology
● Studied in experimental settings for:
o Breast cancer and endometrial cancer (as it inhibits progesterone signaling)
o Psychiatric disorders (e.g., major depression with psychotic features) due to its glucocorticoid receptor blockade
o Leiomyoma (fibroids) and endometriosis management
4. Emergency Contraception (Investigational Use)
● Although not its primary indication, low-dose mifepristone has been studied as a postcoital contraceptive, showing effectiveness in preventing ovulation and implantation when used within a specific timeframe.

1. Non-Invasive Alternative to Surgery
● Mifepristone offers a safe, effective, and less invasive alternative to surgical abortion when used properly under medical guidance.
2. Receptor-Specific Activity
● High affinity for progesterone and glucocorticoid receptors, allowing targeted modulation with limited off-target hormonal effects at therapeutic doses.
3. Expanded Therapeutic Potential
● Its glucocorticoid antagonism opens avenues for treating metabolic disorders, psychiatric illness, and hormone-sensitive cancers.
4. Oral Bioavailability
● Mifepristone is well-absorbed orally and has a long half-life (~20–85 hours), which supports convenient dosing schedules.

Mifepristone丨CAS 84371-65-3 is a powerful and versatile pharmaceutical compound with well-established use in medical abortion and Cushing's syndrome, and promising investigational roles in oncology, reproductive health, and endocrinology. Its dual action as a progesterone and glucocorticoid receptor antagonist allows it to address complex hormone-dependent conditions while providing patients with non-invasive treatment options. Ongoing research continues to explore its broader therapeutic potential in various medical domains.